0 CHECKOUT

Warts - Pipeline Review, H2 2015

  • ID: 3387863
  • July 2015
  • 91 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Biogenomics Limited
  • EpiPharm AG
  • LEO Pharma A/S
  • NanoViricides, Inc.
  • Novan, Inc.
  • MORE

Warts - Pipeline Review, H2 2015

Summary

The report ‘Warts - Pipeline Review, H2 2015’, provides an overview of the Warts’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3M Drug Delivery Systems
  • Biogenomics Limited
  • EpiPharm AG
  • LEO Pharma A/S
  • NanoViricides, Inc.
  • Novan, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Warts Overview
Therapeutics Development
Pipeline Products for Warts - Overview
Pipeline Products for Warts - Comparative Analysis
Warts - Therapeutics under Development by Companies
Warts - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Warts - Products under Development by Companies
Warts - Companies Involved in Therapeutics Development
3M Drug Delivery Systems
Agilvax, Inc.
Biogenomics Limited
BioMAS Ltd.
Biota Pharmaceuticals, Inc.
EpiPharm AG
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Helix BioPharma Corp.
LEO Pharma A/S
MediGene AG
NanoViricides, Inc.
Nielsen Biosciences, Inc.
Novan, Inc.
Novartis AG
Promius Pharma, LLC
RXi Pharmaceuticals Corporation
Tamir Biotechnology, Inc.
Zydus Cadila Healthcare Limited
Warts - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(digoxin + furosemide) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
854-A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-611074 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AX-03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Candida Albicans Antigen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DFD-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
diphencyprone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EPI-N06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HerpeCide-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
human papilloma virus [strains 6,11] (bivalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imiquimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ingenol mebutate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alfa-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon alpha-2b (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LFX-453 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PP-210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranpirnase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sinecatechins - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Cervical Cancer and Genital Warts - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Warts - Recent Pipeline Updates
Warts - Dormant Projects
Warts - Discontinued Products
Warts - Product Development Milestones
Featured News & Press Releases
Feb 20, 2015: Medigene receives positive decision on marketing authorisation for Veregen in 8 additional European countries
Sep 30, 2014: Veregen Marketing Authorization Process initiated for eight additional European countries
Jul 16, 2014: Paladin Labs Announces the Canadian Launch of Veregen
Jun 12, 2014: Medigene announces market launch of Veregen in Belgium, Denmark and Finland
Apr 08, 2014: Medigene and Kora Healthcare sign agreement for the commercialisation of Veregen® in United Kingdom and Ireland
Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden
Dec 18, 2013: Medigene's drug Veregen launched in Norway and Sweden
Dec 11, 2013: Medigene announces Veregen to be launched in the Czech Republic, Poland, Hungary, and Slovakia
Oct 01, 2013: Medigene announces market launch of Veregen in Taiwan
Sep 10, 2013: Medigene's Drug Veregen receives market approval in Canada
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Warts, H2 2015
Number of Products under Development for Warts - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Warts - Pipeline by 3M Drug Delivery Systems, H2 2015
Warts - Pipeline by Agilvax, Inc., H2 2015
Warts - Pipeline by Biogenomics Limited, H2 2015
Warts - Pipeline by BioMAS Ltd., H2 2015
Warts - Pipeline by Biota Pharmaceuticals, Inc., H2 2015
Warts - Pipeline by EpiPharm AG, H2 2015
Warts - Pipeline by Foamix Pharmaceuticals Ltd., H2 2015
Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2015
Warts - Pipeline by Helix BioPharma Corp., H2 2015
Warts - Pipeline by LEO Pharma A/S, H2 2015
Warts - Pipeline by MediGene AG, H2 2015
Warts - Pipeline by NanoViricides, Inc., H2 2015
Warts - Pipeline by Nielsen Biosciences, Inc., H2 2015
Warts - Pipeline by Novan, Inc., H2 2015
Warts - Pipeline by Novartis AG, H2 2015
Warts - Pipeline by Promius Pharma, LLC, H2 2015
Warts - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
Warts - Pipeline by Tamir Biotechnology, Inc., H2 2015
Warts - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Warts Therapeutics - Recent Pipeline Updates, H2 2015
Warts - Dormant Projects, H2 2015
Warts - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Warts, H2 2015
Number of Products under Development for Warts - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

3M Drug Delivery Systems
Agilvax, Inc.
Biogenomics Limited
BioMAS Ltd.
Biota Pharmaceuticals, Inc.
EpiPharm AG
Foamix Pharmaceuticals Ltd.
G&E Herbal Biotechnology Co., Ltd.
Helix BioPharma Corp.
LEO Pharma A/S
MediGene AG
NanoViricides, Inc.
Nielsen Biosciences, Inc.
Novan, Inc.
Novartis AG
Promius Pharma, LLC
RXi Pharmaceuticals Corporation
Tamir Biotechnology, Inc.
Zydus Cadila Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.